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Abstract
Background and Objective Patient heterogeneity is the
part of variability that can be explained by certain patient
characteristics (e.g. age, disease stage). Population reim-
bursement decisions that acknowledge patient heterogene-
ity could potentially save money and increase population
health. To date, however, economic evaluations pay only
limited attention to patient heterogeneity. The objective of
the present paper is to provide a comprehensive overview
of the current knowledge regarding patient heterogeneity
within economic evaluation of healthcare programmes.
Methods A systematic literature review was performed to
identify methodological papers on the topic of patient
heterogeneity in economic evaluation. Data were obtained
using a keyword search of the PubMed database and
manual searches. Handbooks were also included. Relevant
data were extracted regarding potential sources of patient
heterogeneity, in which of the input parameters of an
economic evaluation these occur, methods to acknowledge
patient heterogeneity and specific concerns associated with
this acknowledgement.
Results A total of 20 articles and five handbooks were
included. The relevant sources of patient heterogeneity
(demographics, preferences and clinical characteristics)
and the input parameters where they occurred (baseline
risk, treatment effect, health state utility and resource
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utilization) were combined in a framework. Methods were
derived for the design, analysis and presentation phases of
an economic evaluation. Concerns related mainly to the
danger of false-positive results and equity issues.
Conclusion By systematically reviewing current knowl-
edge regarding patient heterogeneity within economic
evaluations of healthcare programmes, we provide guid-
ance for future economic evaluations. Guidance is provided
on which sources of patient heterogeneity to consider, how
to acknowledge them in economic evaluation and potential
concerns. The improved acknowledgement of patient het-
erogeneity in future economic evaluations may well
improve the efficiency of healthcare.
Key Points for Decision Makers
• Patient heterogeneity not only impacts relative
treatment effects: its impact on baseline risk, utility
and resource utilization should be acknowledged in
economic evaluations
• General sources of patient heterogeneity are demo-
graphics, preferences and clinical characteristics
• Different methods for acknowledging patient hetero-
geneity in an economic evaluation are available for
the design, analysis and presentation phases
• Potential equity concerns and resulting opportunity
losses associated with acknowledging heterogeneity
in economic evaluations should be presented
1 Introduction
Heterogeneity can be defined as ‘diversity in character or
content’ [1]. In medical research, heterogeneity is depicted
as the part of variability (the natural variation between
patients) that can be explained by certain patient charac-
teristics, such as age or stage of the disease [2]. This type of
heterogeneity, which is referred to as patient heterogeneity,
may influence the cost effectiveness of a treatment. Patient
heterogeneity should be distinguished from differences in
the nature of the treatment (e.g. different drug doses or
different techniques used) or in the geographical region
(transferability) that may impact cost effectiveness. These
factors relate more to the generalizability of cost-effec-
tiveness results [3] and are beyond the scope of this paper.
The present paper collects available knowledge on
acknowledging patient heterogeneity in the economic
evaluation of healthcare programmes.
In healthcare, it has been recognized that patients differ
in their response to treatment. Therefore, treatments are
becoming increasingly tailored to the individual patient
[4, 5]. At the same time, average results of economic
evaluations for patient groups are used to assist population
reimbursement decisions upon new healthcare programmes
[6, 7]. Average population-based economic evaluations,
however, can mask important sources of patient heteroge-
neity within a patient population that may be important to
improve population reimbursement decisions [7, 8]. For
example, a programme that is deemed cost effective for a
subpopulation may not be reimbursed because another
subpopulation has a poorer outcome, and therefore on
average it is not cost effective for all patients with that
particular disease. This would result in health benefits
forgone, as a subgroup of patients does not receive the
optimal treatment. Or, inefficiency occurs because a pro-
gramme is reimbursed based on its average cost effec-
tiveness for the total population, while it may not be cost
effective for a subpopulation of these patients. This would
result in suboptimal use of scarce resources. Hence ignor-
ing patient heterogeneity could be costly both in monetary
terms and in health gain. Coyle et al. [9] for example
showed that by acknowledging patient heterogeneity in the
treatment of acute myocardial infarction a considerable
monetary gain could be achieved. Basu and Meltzer [10]
calculated that acknowledging patient heterogeneity in
prostate cancer patients in the USA could even result in
US$70 million gained annually. They argue that the value
of reflecting patient heterogeneity in reimbursement deci-
sions can be far greater than the value of improved decision
making at the population level [10]. Population reim-
bursement decisions that acknowledge patient heterogene-
ity could save money and increase population health.
Obviously, this is only possible if the patient heterogeneity
is known at the moment a treatment decision is made. This
paper therefore focuses on observed patient heterogeneity,
on which population reimbursement decisions could be
based.
To date, only limited attention is paid in economic
evaluations to patient heterogeneity. In clinical studies
patient heterogeneity is often examined in terms of treat-
ment effect [6, 7]. It is then examined whether heteroge-
neity exists in the relative treatment effect, using measures
like relative risks, odds ratios or hazard ratios. This infor-
mation, however, is insufficient for economic evaluations,
as homogeneity in treatment effects from a clinical point of
view does not necessarily imply homogeneity in cost
effectiveness [6]. However, there is no systematic overview
of which sources of patient heterogeneity exist and in
which of the input parameters of an economic evaluation
they may occur. Additionally, pharmacoeconomic guide-
lines provide hardly any methodological guidance on
acknowledging heterogeneity [11]. Moreover, reflecting
patient heterogeneity in reimbursement decisions may
have ethical implications if it leads to limiting financial
access to certain groups of individuals. For example, it is
112 J. P. C. Grutters et al.
questionable whether policy makers are willing to reim-
burse a treatment only for a subgroup of patients, when this
subgroup is based on race [12].
The objective of the present paper is to provide a
comprehensive overview of the current knowledge
regarding patient heterogeneity within economic evalua-
tions of healthcare programmes. More specifically, we aim
to address the following research questions:
1. Which sources of patient heterogeneity can be
relevant in economic evaluation and in which of the
input parameters of an economic evaluation can they
occur?
2. Which methods can be used for acknowledging patient
heterogeneity in an economic evaluation?
3. What concerns exist with regard to acknowledging
patient heterogeneity in economic evaluation and
population reimbursement decisions?
2 Methods
2.1 Search Strategy and Selection Criteria
A systematic literature review was performed to identify
methodological papers on the topic of patient heterogeneity
in economic evaluation. We used the electronic database
PubMed to search for peer-reviewed full papers, published
before 2011. The electronic search term was as follows:
(‘heterogeneity’) and (‘cost-effectiveness’ or ‘economic
evaluation’). Additional references were searched through
manual searches of the reference lists of retrieved papers
and specialist journals, and through discussion with the
authors. Studies were included only if they were written in
English, had an explicit methodological objective (i.e.
objective, keywords or publication type includes ‘meth-
odology’ or ‘methods’; or objective is to ‘discuss’, ‘pro-
pose’, ‘develop’, or ‘argue for change in economic
evaluation’), and considered patient heterogeneity that is
potentially known at the time of treatment decision. Papers
were excluded if the main goal was to report outcomes, if
they concerned heterogeneity not related to patients (e.g.
heterogeneity in the nature of the treatment or issues
relating to transferability) or if they concerned other
methodological issues. Two authors (MJ, JG) indepen-
dently reviewed the titles, abstracts and, if necessary, full
papers, to determine whether a paper met the inclusion
criteria. Discrepancies were solved by all authors in a
consensus meeting. Additionally, handbooks on economic
evaluation were searched for recommendations on patient
heterogeneity. Expert consensus by all authors was used to
determine whether the most important papers and hand-
books were included.
2.2 Data Extraction and Analysis
Relevant data were extracted from the publications by two
authors (JG, MJ) independently. First, for all included
publications we retrieved the sources of patient heteroge-
neity that were mentioned in their examples, and in which
of the input parameters of an economic evaluation this
heterogeneity occurred. With input parameters, we refer to
the data inputs of an economic evaluation in general, be it a
trial-based or a model-based economic evaluation. Subse-
quently, these sources and input parameters were combined
in a framework, in order to allow for a systematic con-
sideration of patient heterogeneity in economic evalua-
tions. Second, from the publications that explicitly
mentioned methods to acknowledge patient heterogeneity,
we extracted these methods. Methods were categorized into
methodology for the design (e.g. choosing trial outcomes,
collecting model input parameters, designing model
structure), analysis (e.g. analysing costs, effects, cost
effectiveness, uncertainty) and presentation (e.g. presenta-
tion of costs, effects, cost effectiveness, uncertainty) phases
of an economic evaluation [6]. Methods were extracted for
both trial-based and model-based economic evaluations. If
a method is only useful for one type of economic evalua-
tion (model or trial), this is specified. Third, we extracted
specific concerns that were mentioned with regard to
acknowledging patient heterogeneity. Discrepancies were
solved in a consensus meeting with the authors.
3 Results
3.1 Selected Sources and Characteristics
On the basis of the keywords, 231 articles were found
(Fig. 1). A total of 220 articles were excluded because they
were not deemed relevant, which left a total number of ele-
ven studies included in the review [7–10, 13–19]. Most
excluded references reported on heterogeneity between
studies or differences in the nature of treatment instead of
patient heterogeneity. Five additional articles were retrieved
through manual searches of the reference lists and discussion
with the authors [12, 20–23]. Four additional publications
were included because they were responses to the included
references [24–27]. The 20 included studies were published
between 2001 [23] and 2010 [22]. Five handbooks on eco-
nomic evaluation were included in the review [2, 6, 29,
48, 49]. All included publications are listed in Table 1.
3.2 Sources of Patient Heterogeneity
Table 1 summarizes the sources of patient heterogeneity
that were used as examples in the included publications.
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The columns describe the input parameters of an economic
evaluation where the patient heterogeneity occurred in the
examples.
Based on Table 1 we developed a framework to sys-
tematically consider patient heterogeneity in economic
evaluations. Economic evaluations consider both costs and
effects. Regarding the costs, patient heterogeneity will not
occur in unit costs, as these are likely to be independent of
patient characteristics. Differences in unit costs are more
likely a result of differences between jurisdictions, which is
an issue of transferability [28]. Resource utilization, how-
ever, may well be affected by characteristics of the patient.
Regarding the effects, from Table 1 it was clear that there
may be patient heterogeneity in baseline risk (e.g. treat-
ment-independent probability of a clinical event, mortality
rate, incidence), treatment effect and health state utility.
Heterogeneity in the treatment effect is the most recog-
nized form of heterogeneity, as it is also examined in
clinical studies. This mostly refers to heterogeneity in
relative treatment effects such as relative risks, odds ratios
or hazard ratios. Heterogeneity in baseline risk and health
state utility refers to absolute effects, which are also of
importance in economic evaluations.
Demographic characteristics of a patient, such as age,
sex, intelligence and race, may be a source of patient
heterogeneity. Preferences may also be a source of heter-
ogeneity, for example because of differences in beliefs,
attitude or risk tolerance. Finally, several clinical charac-
teristics that relate to the disease were mentioned as a
source of heterogeneity, such as severity, disease history
and genetic profile. In the framework, we consider genetic
factors such as pharmacogenetic heterogeneity to be clin-
ical characteristics. The framework to consider patient
heterogeneity in economic evaluations therefore consists of
three general sources of patient heterogeneity (demo-
graphics, preferences and clinical characteristics) that may
N = 231






















Responses to included 
publications
+4
Fig. 1 Flow diagram of the
search results






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Patient Heterogeneity in Economic Evaluation 115
impact four input parameters of economic evaluations
(baseline risk, treatment effect, health state utility and
resource utilization) [Fig. 2].
3.3 Methodology to Acknowledge Patient
Heterogeneity
Sixteen publications describe methodology to acknowledge
heterogeneity in the design, analysis or presentation phase
of an economic evaluation [2, 6, 7, 9, 10, 12, 14–21, 23,
29]. In any economic evaluation, stratified analyses of cost
effectiveness (in the most extreme case stratified to N = 1)
are needed to inform whether patient heterogeneity should
be reflected in the reimbursement decision. The identified
methodologies can be used to allow for such stratified
analyses. Six publications describe methodology for use in
the design phase [2, 14, 15, 18, 19, 23]. The most com-
prehensive methodology to acknowledge patient hetero-
geneity in an economic evaluation in this phase is provided
by Briggs et al. [2]. They provide detailed guidance as to
how regression methods can be used in a decision model to
relate input parameters (e.g. survival, event probability) to
a patient characteristic. These methods can be used in
models that simulate cohorts of patients as well as in
models that simulate individual patients. The authors
describe a number of regression models that can be used
depending on the nature of the data [2]. In line with this,
three publications propose to use different input values for
different subgroups of patients [18, 19, 23]. Both Brennan
et al. [14] and Heeg et al. [15] state that stratified analyses
are possible to acknowledge heterogeneity in models that
simulate cohorts of patients, but this may not be ideal
depending on the size of the model and the number of
subgroups. Brennan et al. [14] describe that different sub-
groups (based on, for example, baseline risk) can start out
in different health states. This way one can take into
account that a specific course of action may differ
depending on the baseline risk, by explicitly modelling this
conditional on the health state. In case this technique
becomes too complex, patient-level simulation provides a
useful alternative to a cohort model [14]. However, strati-
fied analyses will still be needed to inform whether patient
heterogeneity should be reflected in the reimbursement
decision.
Nine publications propose specific methods for the
analysis phase of an economic evaluation [6, 9, 10, 12, 16,
17, 20, 21, 29]. When individual patient data are available
on costs, effects and patient characteristics, the existence of
patient heterogeneity can be analysed through the use of
regression techniques. Hoch et al. [12] were the first to
propose that regression analysis could be used within the
net benefit framework. Two years later, the same authors
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effectiveness analysis by proposing the use of a system of
seemingly unrelated regression equations [20]. This
approach has the advantage of allowing different co-vari-
ates and functional forms for the two equations (for costs
and effects). Nixon and Thompson [21] further developed
this regression approach by proposing a coherent set of
Bayesian methods that consider costs and effects jointly,
and that allow for the usual skewness of cost data. Drum-
mond et al. [6], Hoch and Dewa [16] and Marshall and Hux
[17] all propose regression methods to explore subgroups,
referring to the above-mentioned studies. Glick et al. [29]
also propose regression techniques, but only to examine
whether there is heterogeneity in the costs. It should be
noted that the use of regression techniques informs about
the subgroups that are statistically significant, but these
techniques do not pronounce on the clinical relevance and
relevance with regard to costs of a subgroup for reim-
bursement decisions. Additionally, regression techniques
can lead to false-positive results if many subgroups are
investigated or if they are not specified in advance of
looking at the data [21].
Coyle et al. [9] propose to quantify the efficiency gains
resulting from subgroup policy, which relates more to the
relevance of potential subgroups. They provide a frame-
work to calculate the net monetary benefit (NMB) of dif-
ferent subgroup policies, to examine whether subgroup
policy is valuable and which subgroup policy is the most
valuable. When comparative data on costs and effects are
available for each individual patient, the expected value of
individualizing care (EVIC) can be calculated. In this
technique, proposed by Basu and Meltzer [10], the value of
optimal decision making based on population-based aver-
ages is compared with the value of incorporating individ-
ual-level values of heterogeneous parameters (in their
example individual preferences) in the decision-making
process. They calculate the monetary gain that can be
obtained through giving patients the treatment that is cost
effective for that particular individual patient, compared
with giving patients the treatment that is on average cost
effective.
In the presentation of an economic evaluation, Briggs
et al. [2] propose to present full results, including multiple
cost-effectiveness acceptability curves, for subgroups of
patients. Additionally, it is advised to present possible
equity constraints that may be relevant, and their resulting
opportunity losses [7, 9]. For example, if there are potential
equity concerns regarding subgroup policy based on age,
this should be presented, as well as the opportunity losses
associated with (not) reimbursing the treatment for all age
groups [9].
All methods are listed in Table 2. They are illustrated by
hypothetical examples concerning the economic evaluation
of treatments in non-small-cell lung cancer.
3.4 Concerns With Regard to Acknowledging Patient
Heterogeneity
Nine studies specifically describe potential concerns
associated with acknowledging patient heterogeneity [6–9,
13, 20, 21, 24, 25]. Four publications caution for post hoc
stratified analyses and the potential of misleading results
and provide some requirements to avoid such misleading
results [6, 8, 20, 21]. Drummond et al. [6] for example
state that there should always be a plausible clinical
explanation for differences between subgroups of patients,
rather than crude data mining. Nixon and Thompson [21]
in their paper also note the danger of false-positive results
if many subgroups are investigated or if they are not
specified in advance of looking at the data. This danger of
Sources of patient heterogeneity 














































Fig. 2 Overview of the sources of patient heterogeneity that can be relevant in economic evaluation, and the input parameters where they may
occur




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































118 J. P. C. Grutters et al.
false-positive results is also briefly mentioned by Stevens
and Normand [8], who further state that this is more a
statistical problem than an economic one. That is, sub-
groups should not only be statistically significant, but also
relevant for reimbursement decisions. In this light, Willan
et al. [20] mention that the role of stratified analysis in
economic evaluation should be explored in terms of its
importance for policy purposes in comparison with the
usual reluctance to undertake stratified analyses in clinical
evaluation.
Additionally, in a comment to the paper by Bala and
Zarkin [13], La Caze [25] states that pharmacogenomics
provides a challenge to fundamental principles that
underlie most systems for deciding which drugs should be
publicly subsidized. The author provides no solution, but
states that ‘discussion and debate are required to navigate a
line between the extremes while giving due consideration
to both equality and utility’ [25], which was subsequently
agreed upon by Bala and Zarkin [24]. While this discussion
is specific to pharmacogenomics, acknowledging hetero-
geneity in general may cause equity concerns. Sculpher [7]
for example mentions that there may be equity constraints
on which subgroups are used for reimbursement decisions.
In particular, the use of sociodemographic characteristics to
determine which subgroups should have access to a tech-
nology may be considered inequitable. However, this will
depend on whether, for example, a subgroup with a higher
age actually experiences a lower treatment effect, or they
merely have less years of life left and consequently less
QALYs to gain. Also, it may for example be more
acceptable to use subgroup policy based on race when race
for biological reasons impacts the effect of a treatment,
than if race only impacts cost effectiveness through
resource utilization as was found by Willan et al. [20]. This
emphasizes the importance of clarity regarding which input
parameter of an economic evaluation is impacted by the
patient heterogeneity. As was shown by Coyle et al. [9],
equity constraints can impose costs in terms of health
benefits forgone. They propose a framework to quantify the
costs of these possible equity constraints by calculating the
expected opportunity loss (net benefit loss) when gains
from stratification cannot be fully realized due to equity
constraints or professional non-adherence. However, they
do not seek to determine what are and what are not suitable
grounds for the stratification of patients. Sculpher [7] also
mentions that the use of preference subgroups would raise
equity issues. This is for example the case when prefer-
ences differ because of the income of respondents [23].
This equity concern is emphasized by Robinson and Parkin
[26] in a comment on Sculpher and Gafni’s paper [23].
They state that preference subgroups conflict with the idea
that societal welfare is to be determined by aggregation of

























































































































































































































































































































































































































































































Patient Heterogeneity in Economic Evaluation 119
Gafni [27] dispute this conflict because their method uses
societal preferences. The critique is however relevant when
individual preferences are used, as was proposed in two of
the included papers [10, 13].
4 Discussion
To the best of our knowledge, our paper is the first to
systematically review the current knowledge on acknowl-
edging observed patient heterogeneity in economic evalu-
ation. We found that patient heterogeneity may relate to
patient demographics, their preferences or clinical charac-
teristics, and that it can impact baseline risk, treatment
effect, health state utility and resource utilization. We have
developed a framework that allows researchers and policy
makers to systematically explore which source of patient
heterogeneity could be relevant in each of the input
parameters of an economic evaluation. Additionally, we
have listed the various methods that can be used to account
for patient heterogeneity, such as linking inputs to patient
characteristics, regression methods and quantifying the
value of subgroup or individualized policy. Finally, we
have summarized the statistical and ethical concerns that
may be related to acknowledging patient heterogeneity in
population reimbursement decisions. Our results can pro-
vide guidance for researchers to systematically acknowl-
edge heterogeneity in their assessments. Also, they can
assist policy makers in requesting relevant evidence and
assessing the evidence they base their decisions on.
In the present study, we searched for methodological
papers on the topic of patient heterogeneity. Although our
search was systematic, it may not have been comprehensive.
Our search terms were restricted to heterogeneity and eco-
nomic evaluation, and did not include related terms like
subgroups, individual or variability. Therefore, only 11 of
the 20 included papers were obtained through the initial
search. Five additional papers were found by examining the
reference lists of the included papers and discussion with the
authors, and four additional papers were comments on the
included papers. The three papers that described regression
techniques to identify or define subgroups [12, 20, 21] were
not found in the initial search, but were key publications in
the present paper. These papers were probably not found
because they did not refer to heterogeneity, but to subgroup
analyses. Including more search terms (i.e. subgroup anal-
ysis, variability) might have increased the sensitivity of the
initial search, but also decreased the specificity. Despite the
low sensitivity of the initial electronic search, we are con-
vinced that through searching the reference lists of the
included publications and extensive discussion with the
authors our literature review was sufficiently thorough and
that we have not missed any key publications.
While the present review provides a list of potential
methods for use in economic evaluation, it does not result in
one preferred method. Because most methods serve different
purposes, the choice of method depends more on the data that
are available and the purpose (e.g. in the design or analysis of
an economic evaluation) than on its quality. However, three
different methods were found that all use regression tech-
niques to identify subgroups of patients. In one method, the
NMB is the dependent variable [12], while in the method
presented in a more recent paper by the same authors costs and
effects are separated [20]. Information about whether a patient
characteristic influences NMB through costs or effects can be
very relevant for decision makers, especially with regard to
potential equity concerns. The third method also regards costs
and effects as separate dependent variables, but is more flex-
ible than the second method [21]. The advantage of this
method is that it does not assume Normal distributions, which
may make it more appropriate for real data. However, the
disadvantage is that the method is technically more difficult to
implement. Other regression techniques that are used in the
context of economic evaluation may also be used to explore
heterogeneity, but only these three were explicitly suggested
in the literature. No studies were found that directly compare
different methods. A potential disadvantage of all regression
methods is that they require individual patient data, which
may not always be available. Regardless of the method that is
used, the testing of heterogeneity should be undertaken with
due care and diligence.
Two methods were identified that assess the value of
acknowledging heterogeneity [9, 10]. The EVIC technique
that was proposed by Basu and Meltzer [10] is relatively
new and not yet frequently used. Similar to the expected
value of perfect information (EVPI), the EVIC represents
an upper bound of the monetary gain that can be achieved
in theory. In practice, this upper bound may not be reached,
as due to variability we may not always be able to predict
the optimal treatment for an individual patient (EVIC), just
like we will never reach complete certainty (EVPI).
A recent application of EVIC indicates that it is a useful
and feasible technique on both a clinical and a policy level,
especially when considering the EVIC for specific patient
characteristics (parameter-specific EVIC) [30]. More
studies on either the application or further development of
EVIC are needed to support a widespread use of EVIC to
assess the value of acknowledging heterogeneity in popu-
lation reimbursement decisions.
When reflecting patient heterogeneity in economic
evaluations and population reimbursement decisions, it is
important to be aware of potential equity concerns. As
mentioned by Sculpher [7], whether a subgroup policy will
be deemed acceptable may depend on whether the heter-
ogeneity in cost effectiveness is caused by differences in
treatment effect or in one of the other input parameters.
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Patient heterogeneity in treatment effect is expectedly a
more acceptable ground for subgroup policy. Also, the
source of heterogeneity may be relevant, since a subgroup
policy based on differences in clinical characteristics is
expectedly more acceptable than a subgroup policy based
on patient demographics such as age or race. A special
source of patient heterogeneity is individual preferences.
While Sculpher and Gafni [23] propose to acknowledge
differences in preferences while maintaining the use of
utility values of the general public, both Bala and Zarkin
[13] and Basu and Meltzer [10] suggest the use of indi-
vidual preferences to value health state utility. Techniques
to reflect heterogeneity in preferences when valuing health
state utility are becoming increasingly available [31].
Whether individual preferences should have a role in
population reimbursement decisions is however a topic of
debate [32–35]. Because of the differences in ethical con-
cerns regarding sources of heterogeneity and the input
parameters, it is important that when proposing subgroup
policy it is clear which source of heterogeneity is relevant
and in which of the input parameters of an economic
evaluation this patient heterogeneity occurs. Also, it is
important to quantify the potential costs of equity con-
straints, as proposed by Coyle et al. [9]. With this infor-
mation policy makers can make a trade-off between
efficiency and equity.
From the results of our review, we found that many
papers and handbooks recommend to reflect heterogeneity
by performing economic evaluations for specific patient
groups using stratified analyses. Extensive literature exists
on how to define subgroups based on clinical evidence
[36–43]. However, this clinical heterogeneity relates to
differences on a relative scale (i.e. heterogeneity in mea-
sures such as relative risks, odds ratios and hazard ratios)
[6, 7]. It was clear from the present review that, since
economic evaluations concern absolute benefits, heteroge-
neity in absolute effectiveness, for example because of
differences in baseline risk, health state utility or resource
utilization, should also be acknowledged in economic
evaluations. That is, homogeneity in treatment effects from
a clinical point of view does not necessarily imply homo-
geneity in cost effectiveness. This is nicely illustrated in
cost-effectiveness analyses on cardiovascular disease,
where baseline risk was found to cause heterogeneity in the
cost effectiveness of the intervention [44, 45]. The frame-
work in Fig. 2 allows researchers to systematically explore
whether patient heterogeneity could be relevant in each of
the input parameters of an economic evaluation. This
allows researchers to consider heterogeneity on an absolute
scale. In addition to the difference between heterogeneity
in relative versus absolute effects, two other challenges
arise when using stratified analyses in economic evalua-
tion. First, it is unclear whether policy makers wish to
implement stratified policy if there is no heterogeneity in
the relative treatment effect. By presenting potential sub-
groups and costs of equity constraints, policy makers can
make an informed trade-off between equity and efficiency.
Second, if we incorporate stratified analyses in economic
evaluations, we are uncertain about the definition of our
subgroups, especially when the characteristic is a contin-
uous measure and cut-off points are needed. Ideally this
uncertainty should be incorporated in the economic eval-
uation. For these gaps in current knowledge, future meth-
odological research could generate new knowledge that can
be used when conducting economic evaluations.
Pharmacoeconomic guidelines, which present country-
specific guidelines for conducting economic evaluations,
provide hardly any methodological guidance on acknowl-
edging heterogeneity [11]. As these guidelines have a very
different purpose than original methodological articles, and
the focus of the current review was on original methodol-
ogy, we decided not to include them. However, it would be
an interesting topic for further research to assess to what
extent these guidelines are attuned to the available meth-
odology identified in the current review.
While the present paper contributes to current knowl-
edge, it also highlighted where knowledge was lacking.
Although Sculpher [7] made an important attempt in this
direction, none of the studies provided guidance on the
types of subgroups that should be explored, or how sub-
groups should be defined. By systematically reviewing the
sources of heterogeneity and input parameters where they
may occur, and summarizing them in a concise figure, we
hope to partly provide such guidance. Also, we have
summarized which methods can be used in each phase of
an economic evaluation. This may help researchers to
systematically consider whether patient heterogeneity
should be acknowledged in their economic evaluation, and
how this can be done. Our results may be used in the field
of comparative effectiveness research, where patient het-
erogeneity is recognized, but still very much focused on
heterogeneity in relative treatment effects [46]. Our results
may also facilitate the collection of data within access with
evidence development schemes to examine patient heter-
ogeneity [47]. It could help policy makers and researchers
to agree upon which evidence to collect, and could foster
the acknowledgement of patient heterogeneity, even when
an intervention is on average cost effective for the popu-
lation. In the end, acknowledging patient heterogeneity
may well improve the efficiency of healthcare.
5 Conclusion
By systematically reviewing current knowledge regarding
patient heterogeneity within economic evaluations of
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healthcare programmes, we provide guidance for future
economic evaluations. Guidance is provided on which
sources of patient heterogeneity to consider, how to
acknowledge them in economic evaluation and potential
concerns. The improved acknowledgement of patient het-
erogeneity in future economic evaluations may well
improve the efficiency of healthcare.
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